Clinical Trial Update: Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) [Phase 2]

View source ↗

Summary

Phase II study of aerosolized liposomal 9-nitro-20(S)-camptothecin (L9NC) for endometrial cancer and corpus uteri cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Uterine Cancer

Drugs mentioned

• Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) (9-nitro-20(S)-camptothecin liposomal formulation)

Snippet

Sponsor: University of New Mexico | Conditions: Corpus Uteri, Endometrial Cancer | Phase 2 | Status: COMPLETED